Gilan, Omer http://orcid.org/0000-0003-4156-2619
Talarmain, Laure
Bell, Charles C. http://orcid.org/0000-0003-2194-8311
Neville, Daniel http://orcid.org/0009-0004-1507-6208
Knezevic, Kathy
Ferguson, Daniel T.
Boudes, Marion http://orcid.org/0000-0003-2577-710X
Chan, Yih-Chih http://orcid.org/0000-0003-2177-5406
Davidovich, Chen http://orcid.org/0000-0002-1085-6094
Lam, Enid Y. N. http://orcid.org/0000-0001-5843-7836
Dawson, Mark A. http://orcid.org/0000-0002-5464-5029
Article History
Received: 3 January 2023
Accepted: 3 August 2023
First Online: 7 September 2023
Competing interests
: M.A.D. has been a member of advisory boards for GSK, CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. The Dawson Laboratory is a recipient of grant funding through the emerging science fund administered through Pfizer. The remaining authors declare no competing interests.